Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 77-81

  Davidson, Bruce L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Acutely ill patients; Critically ill patients; Sepsis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBOLISM; HEART VENTRICLE THROMBOSIS; HUMAN; LUNG EMBOLISM; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; STROKE; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0034456193     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054168     Document Type: Conference Paper

References (23)

1. The relationship between the thrombotic and infectious complications of central venous catheters
2. Benefit of heparin in central venous and pulmonary artery catheters: A meta-analysis of randomized controlled trials
3. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications
4. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease
5. Does heart failure confer a hypercoagulable state? Virchow's triad revisited
6. Recognition and management of preoperative risk
7. Pathophysiology of the thrombophilic state in the cancer patient
8. A prospective study of venous thromboembolism after major trauma
9. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
10. Prevention of venous thromboembolism
11. Prevention of venous thromboembolism
12. Prevention of venous thromboembolism
13. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit
14. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
15. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study
16. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke
17. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study
18. Low-molecular-weight heparin for the treatment of acute ischemic stroke
19. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study
20. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
21. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty
22. The influence of creatinine clearance on maximal and steady state factor Xa inhibitory capacity following low molecular weight heparin administration
23. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin